RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Juwon Park to Signal Transduction

This is a "connection" page, showing publications Juwon Park has written about Signal Transduction.
Connection Strength

0.179
  1. Park J, Bae EK, Lee C, Choi JH, Jung WJ, Ahn KS, Yoon SS. Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-?B-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis. BMB Rep. 2014 May; 47(5):274-9.
    View in: PubMed
    Score: 0.067
  2. Park J, Kim KI, Koh Y, Won NH, Oh JM, Lee DS, Kim BK, Ahn KS, Yoon SS. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model. Exp Hematol. 2010 Sep; 38(9):773-81.
    View in: PubMed
    Score: 0.051
  3. Park J, Ahn KS, Bae EK, Kim BS, Kim BK, Lee YY, Yoon SS. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells. Anticancer Drugs. 2008 Sep; 19(8):777-82.
    View in: PubMed
    Score: 0.045
  4. Lee C, Oh JI, Park J, Choi JH, Bae EK, Lee HJ, Jung WJ, Lee DS, Ahn KS, Yoon SS. TNF a mediated IL-6 secretion is regulated by JAK/STAT pathway but not by MEK phosphorylation and AKT phosphorylation in U266 multiple myeloma cells. Biomed Res Int. 2013; 2013:580135.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support